Corporate venture capital fund of the Angelini group investing in biotechs.
Profile being verified
What they look for
Co-led the Series B extension of NUCLIDIUM (Regina Hodits, managing director). It has followed Nouscom since its Series C and is participating in its new round, which Angelini Industries is joining via Angelini Investments.
Recent investments
Recorded Swiss rounds: NUCLIDIUM (Series B, CHF 26 M, May 2026, co-lead), Nouscom (Series C, USD 135 M, October 2026).